interleukin-12
Recombinant proteinexperimental
Interleukin 12 (IL-12) is an interleukin that is naturally produced by dendritic cells, macrophages, neutrophils, helper T cells and human B-lymphoblastoid cells (NC-37) in response to antigenic stimulation. IL-12 belongs to the family of interleukin-12. IL-12 family is unique in comprising the only heterodimeric cytokines, which includes IL-12, IL-23, IL-27 and IL-35. Despite sharing many structural features and molecular partners, they mediate surprisingly diverse functional effects. — Wikipedia
Clinical trial activity
62 trials · 39 clinical orgs · 0 marketing orgs
Phase 1
37
Phase 2
33
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 1997 (NCT00019188)
Timeline
Indications
Studied for
- Acquired Immunodeficiency Syndrome · Phase 1
- Adrenocortical Carcinoma · Phase 1
- Alphapapillomavirus · Phase 1/Phase 2
- Anus Neoplasms · Phase 1/Phase 2
- Appendix · Phase 1
- Bile Duct Neoplasms · Phase 1
- Breast Neoplasms · Phase 2
- Breast Neoplasms, Male · Phase 1
- Carcinoma · Phase 1/Phase 2
- Carcinoma, Adenoid Cystic · Phase 1
- Carcinoma, Islet Cell · Phase 1
- Carcinoma, Mucoepidermoid · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Squamous Cell · Phase 1
- Colonic Neoplasms · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2
- Colostomy · Phase 2
- Cryptosporidiosis · Phase 1/Phase 2
- Endometrial Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 1
- Gallbladder Neoplasms · Phase 1
- Gastrinoma · Phase 1
- Gestational Trophoblastic Disease · Phase 1
- Glioblastoma · Phase 1/Phase 2
- Glioma · Phase 1/Phase 2
- Glucagonoma · Phase 1
- Hamartoma · Phase 2
- Head and Neck Neoplasms · Phase 1/Phase 2
- HIV Infections · Phase 1/Phase 2
- Hodgkin Disease · Phase 2
- Human papillomavirus 16 · Phase 1/Phase 2
- Immunologic Factors · Phase 1/Phase 2
- Inflammatory Breast Neoplasms · Phase 1
- Insulinoma · Phase 1
- Intestinal Neoplasms · Phase 1
- Kidney Neoplasms · Phase 1
- Leishmaniasis, Cutaneous · Phase 1
- Leukemia · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Liver Neoplasms · Phase 1
- Lung Neoplasms · Phase 1
- Lymphoma · Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 2
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, T-Cell · Phase 2
- Melanoma · Phase 2
- Multiple Myeloma · Phase 2
- Mycobacterium avium-intracellulare Infection · Phase 1
- Mycobacterium Infections, Nontuberculous · Phase 1
- Mycosis Fungoides · Phase 2
- Myelodysplastic Syndromes · Phase 1
- Myeloproliferative Disorders · Phase 1
- Neoplasm Metastasis · Phase 1/Phase 2
- Neoplasms · Phase 2
- Neoplasms, Nerve Tissue · Phase 1/Phase 2
- Neoplasms, Neuroepithelial · Phase 1/Phase 2
- Neuroblastoma · Phase 1
- Neuroectodermal Tumors · Phase 1/Phase 2
- Oropharyngeal Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1
- Penile Neoplasms · Phase 1/Phase 2
- Pleural Effusion, Malignant · Phase 1
- Precancerous Conditions · Phase 1
- Prostatic Neoplasms · Phase 2
- Radiation Oncology · Phase 2
- Rectal Neoplasms · Phase 1
- Salivary Gland Neoplasms · Phase 1
- Sarcoma · Phase 2
- Sarcoma, Kaposi · Phase 1/Phase 2
- Sezary Syndrome · Phase 2
- Small Cell Lung Carcinoma · Phase 1
- Somatostatinoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 1
- Testicular Neoplasms · Phase 1
- Thyroid Carcinoma, Anaplastic · Phase 1
- Thyroid Neoplasms · Phase 1
- Urethral Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
- Uterine Cervical Neoplasms · Phase 2
- Vaccines · Phase 1/Phase 2
- Vaginal Neoplasms · Phase 1/Phase 2
- Vipoma · Phase 1
- Vulvar Neoplasms · Phase 1/Phase 2
- Waldenstrom Macroglobulinemia · Phase 2
Mechanism of action
- Interleukin-12 subunit betaSupplementation
IL12B supplementation
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaInterleukin 12 ↗
- NCATS02FXP10O2U ↗
- ChEMBLCHEMBL5095343 ↗
- ChEMBLCHEMBL4298056 ↗
Also known as
- il-12
- interleukin-12
- nm-il-12
- pil-12
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04708470 | Phase 1/Phase 2 (Phase 2) | Oct 5, 2021 | National Cancer Institute (NCI) |
| NCT04756505 | Phase 1 | Mar 7, 2021 | University of Texas at Houston |
| NCT04388033 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2020 | Zhejiang University |
| NCT04491955 | Phase 2 | Sep 22, 2020 | National Cancer Institute (NCI) |
| NCT04303117 | Phase 1/Phase 2 (Phase 2) | Apr 23, 2020 | National Cancer Institute (NCI) |
| NCT04287868 | Phase 1/Phase 2 (Phase 2) | Mar 9, 2020 | National Cancer Institute (NCI) |
| NCT03030378 | Phase 1 | Aug 11, 2017 | National Cancer Institute (NCI), University of Pittsburgh |
| NCT02994953 | Phase 1 | Jan 1, 2017 | Merck KGaA, Merck Serono |
| NCT02544724 | Phase 2 | Nov 1, 2016 | Hebrew University, Neumedicines Inc. |
| NCT02542124 | Phase 2 | Dec 1, 2015 | National Cancer Institute (NCI), Neumedicines Inc., Stanford University |
| NCT02544061 | Phase 2 | Dec 1, 2015 | Neumedicines Inc., United States Army, Washington University in St. Louis |
| NCT02483312 | Phase 1 | Sep 1, 2015 | Ozmosis Research Inc., University of Toronto |
| NCT02493361 | Phase 2 | Jul 1, 2015 | University of California, San Francisco |
| NCT02345330 | Phase 2 | May 1, 2015 | OncoSec Medical Incorporated |
| NCT02343133 | Phase 2 | Jan 1, 2015 | Covance, Department of Health and Human Services, Neumedicines Inc. |
| NCT01742221 | Phase 1 | Aug 1, 2012 | Covance, Department of Health and Human Services, Neumedicines Inc. |
| NCT01502293 | Phase 2 | Dec 1, 2011 | OncoSec Medical Incorporated |
| NCT01468896 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2011 | National Cancer Institute (NCI), Ohio State University |
| NCT01417546 | Phase 1 | Jul 29, 2011 | National Cancer Institute (NCI) |
| NCT01266616 | Phase 1 | Mar 1, 2011 | Drexel University, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 20 of 62 trials
Page 1 / 4
Organizations
Research & Development (39)
39 organizations
Page 1 / 2